Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Foran, J M ^a   Cunningham, D ^b   Coiffier, B ⁱ   Solal Celigny, P ^c   Reyes, F ^d   Ghielmini, M ^e   Johnson, P W M ^f   Gisselbrecht, C ^g   Bradburn, M ^h   Matthews, J ^a   Lister, T A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c CENTRE JEAN BERNARD   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e OSPEDALE SAN GIOVANNI   (Switzerland)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g SAINT LOUIS HOSPITAL   (France)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ NONE

Author keywords

Anti CD20; Chimeric monoclonal antibody; Mantle cell lymphoma; R.E.A.L. Classification; Rituximab

Indexed keywords

ALKYLATING AGENT; FLUDARABINE PHOSPHATE; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 0006818262     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S117     Document Type: Conference Paper

References (20)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18.
2. Norton AJ, Matthews J, Pappa V et al. Mantle-cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6: 249-56.
3. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle-cell lymphoma. Ann Oncol 1995; 6: 257-62.
4. Hiddemann W, Brittinger G, Tiemann M et al. Clinical characteristics and response to chemotherapy of mantle-cell lymphoma results of a European survey. Proc Am Soc Hem 1996; 88 (Suppl 1): 674a.
5. Reff ME, Carner K, Chambers KS et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
6. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
7. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
8. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase-II study. Blood 1998; 92: 1927-32.
9. Foran JM, Rohatiner AZS, Cunningham D et al. Immunotherapy of mantle-cell lymphoma, lymphoplasmacytoid lymphoma and Waldenstrom's macroglobulinemia, and small lymphocytic lymphoma with Rituximab (IDEC-C2B8): Preliminary results of an ongoing international multicentre trial. Proc Int Soc Hematol Eur Hematol Assoc Combined Congress (Br J Haematol) 1998; 102: 586a.
10. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
11. Stansfeld AG, Diebold J, Noel H et al. Updated Kiel Classification for lymphomas. Lancet 1988; 1 (8580): 292-3 (Letter).
12. Harris NL, Jaffe ES, Stein H et al. A revised European - American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
13. Greene WH. Econometric Analysis, second edition. New York: MacMillan 1993.
14. Kaplan ES and Meier P. Non-parametric estimation from incomplete observation. Am Stats Assoc J 1958; 53: 457-80.
15. Meusers P, Engelhard M, Bartels H et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 1989; 7: 365-80.
16. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone-marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 1998; 16: 13-8.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
18. Lopez-Guillermo A, Montserrat E, Bosch F et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphomas. J Clin Oncol 1994; 12: 1343-8.
19. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
20. Link BK, Grossbard ML, Fisher RI et al. Phase-II pilot study of the safety and efficacy of Rituximab in combination with CHOP chemotherapy in patients with previously-untreated intermediate-or high-grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1998; 17: 7a (Abstr).